BACKGROUND: The Diabetes Control and Complications Trial (DCCT) showed a beneficial effect of 6.5 years of intensive glycemic control on retinopathy in patients with type 1 diabetes. METHODS:Between 1983 and 1989, a total of 1441 patients with type 1 diabetes in the DCCT were randomly assigned to receive either intensive diabetes therapy or conventional therapy aimed at preventing hyperglycemic symptoms. They were treated and followed until 1993. Subsequently, 1375 of these patients were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. The self-reported history of ocular surgical procedures was obtained annually. We evaluated the effect of intensive therapy as compared with conventional therapy on the incidence and cost of ocular surgery during these two studies. RESULTS: Over a median follow-up of 23 years, 130 ocular operations were performed in 63 of 711 patients assigned to intensive therapy (8.9%) and 189 ocular operations in 98 of 730 patients assigned to conventional therapy (13.4%) (P<0.001). After adjustment for DCCT baseline factors, intensive therapy was associated with a reduction in the risk of any diabetes-related ocular surgery by 48% (95% confidence interval [CI], 29 to 63; P<0.001) and a reduction in the risk of all such ocular procedures by 37% (95% CI, 12 to 55; P=0.01). Forty-two patients who received intensive therapy and 61 who received conventional therapy underwent cataract extraction (adjusted risk reduction with intensive therapy, 48%; 95% CI, 23 to 65; P=0.002); 29 patients who received intensive therapy and 50 who received conventional therapy underwent vitrectomy, retinal-detachment surgery, or both (adjusted risk reduction, 45%; 95% CI, 12 to 66; P=0.01). The costs of surgery were 32% lower in the intensive-therapy group. The beneficial effects of intensive therapy were fully attenuated after adjustment for mean glycated hemoglobin levels over the entire follow-up. CONCLUSIONS:Intensive therapy in patients with type 1 diabetes was associated with a substantial reduction in the long-term risk of ocular surgery. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360893 and NCT00360815.).
RCT Entities:
BACKGROUND: The Diabetes Control and Complications Trial (DCCT) showed a beneficial effect of 6.5 years of intensive glycemic control on retinopathy in patients with type 1 diabetes. METHODS: Between 1983 and 1989, a total of 1441 patients with type 1 diabetes in the DCCT were randomly assigned to receive either intensive diabetes therapy or conventional therapy aimed at preventing hyperglycemic symptoms. They were treated and followed until 1993. Subsequently, 1375 of these patients were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. The self-reported history of ocular surgical procedures was obtained annually. We evaluated the effect of intensive therapy as compared with conventional therapy on the incidence and cost of ocular surgery during these two studies. RESULTS: Over a median follow-up of 23 years, 130 ocular operations were performed in 63 of 711 patients assigned to intensive therapy (8.9%) and 189 ocular operations in 98 of 730 patients assigned to conventional therapy (13.4%) (P<0.001). After adjustment for DCCT baseline factors, intensive therapy was associated with a reduction in the risk of any diabetes-related ocular surgery by 48% (95% confidence interval [CI], 29 to 63; P<0.001) and a reduction in the risk of all such ocular procedures by 37% (95% CI, 12 to 55; P=0.01). Forty-two patients who received intensive therapy and 61 who received conventional therapy underwent cataract extraction (adjusted risk reduction with intensive therapy, 48%; 95% CI, 23 to 65; P=0.002); 29 patients who received intensive therapy and 50 who received conventional therapy underwent vitrectomy, retinal-detachment surgery, or both (adjusted risk reduction, 45%; 95% CI, 12 to 66; P=0.01). The costs of surgery were 32% lower in the intensive-therapy group. The beneficial effects of intensive therapy were fully attenuated after adjustment for mean glycated hemoglobin levels over the entire follow-up. CONCLUSIONS: Intensive therapy in patients with type 1 diabetes was associated with a substantial reduction in the long-term risk of ocular surgery. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360893 and NCT00360815.).
Authors: Ian H de Boer; Maryam Afkarian; Tessa C Rue; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Wanjie Sun; Bernard Zinman Journal: J Am Soc Nephrol Date: 2014-06-12 Impact factor: 10.121
Authors: Nour Maya N Haddad; Jennifer K Sun; Samer Abujaber; Deborah K Schlossman; Paolo S Silva Journal: Semin Ophthalmol Date: 2014 Sep-Nov Impact factor: 1.975
Authors: Vincent M Monnier; David R Sell; Christopher Strauch; Wanjie Sun; John M Lachin; Patricia A Cleary; Saul Genuth Journal: J Diabetes Complications Date: 2012-11-12 Impact factor: 2.852
Authors: Michael A Grassi; Wanjie Sun; Sapna Gangaputra; Patricia A Cleary; Larry Hubbard; John M Lachin; Xiaoyu Gao; Szilárd Kiss; Andrew J Barkmeier; Arghavan Almony; Matthew Davis; Ronald Klein; Ronald P Danis Journal: Ophthalmology Date: 2013-07-24 Impact factor: 12.079
Authors: John M Lachin; Neil H White; Dean P Hainsworth; Wanjie Sun; Patricia A Cleary; David M Nathan Journal: Diabetes Date: 2014-09-09 Impact factor: 9.461
Authors: Zhuo Chen; Feng Miao; Andrew D Paterson; John M Lachin; Lingxiao Zhang; Dustin E Schones; Xiwei Wu; Jinhui Wang; Joshua D Tompkins; Saul Genuth; Barbara H Braffett; Arthur D Riggs; Rama Natarajan Journal: Proc Natl Acad Sci U S A Date: 2016-05-09 Impact factor: 11.205
Authors: David M Nathan; Ionut Bebu; Dean Hainsworth; Ronald Klein; William Tamborlane; Gayle Lorenzi; Rose Gubitosi-Klug; John M Lachin Journal: N Engl J Med Date: 2017-04-20 Impact factor: 91.245
Authors: Dean P Hainsworth; Ionut Bebu; Lloyd P Aiello; William Sivitz; Rose Gubitosi-Klug; John Malone; Neil H White; Ronald Danis; Amisha Wallia; Xiaoyu Gao; Andrew J Barkmeier; Arup Das; Shriji Patel; Thomas W Gardner; John M Lachin Journal: Diabetes Care Date: 2019-03-04 Impact factor: 19.112